Nanocarrier-Based Precision Therapeutics for Chronic Lung Diseases: Emerging Strategies and Translational Advances
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".
Deadline for manuscript submissions: 31 October 2026 | Viewed by 124
Special Issue Editors
Interests: COPD; asthma; respiratory infections
Interests: chronic inflammation; biological and metabolic biomarkers; metabolomics; inflammatory mechanisms in cardiopulmonary diseases; immune dysregulation; cardiovascular comorbidities; translational and precision medicine
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Chronic respiratory diseases remain among the leading causes of long-term morbidity worldwide. Diseases like COPD, asthma, and pulmonary fibrosis are characterized by complex inflammatory responses and tissue changes in the lungs. Although various therapeutic agents have been identified to treat these diseases, the therapeutic activity of these agents depends upon how effectively the drug delivery reaches the affected tissues in the lungs with minimal systemic exposure. The clinical application of nanotechnology has been identified as a promising research area to treat lung diseases. Various nanotechnologies, such as liposomes, polymeric nanoparticles, lipid nanoparticles, dendrimers, and extracellular vesicles, are currently being researched for drug delivery applications. By modifying their physicochemical characteristics, these systems could enhance the stability of drugs and affect the distribution and release of therapeutic agents in the pulmonary environment.
In this Special Issue, we aim to provide the latest perspectives on the use of nanocarrier-based approaches for the diagnosis and treatment of chronic respiratory diseases and highlight research that may help guide the development of more specific respiratory therapies.
Dr. Cristian Cojocaru
Dr. Elena Cojocaru
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- nanocarriers
- pulmonary drug delivery
- chronic lung diseases
- precision medicine
- nanomedicine
- targeted therapy
- inhalable nanoparticles
- gene and RNA delivery
- pulmonary inflammation
- translational nanotechnology
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
